What type of study is this?

September 30, 2025

Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

This study highlights the characteristics of patients with advanced triple-negative breast cancer treated with new drug combinations.
Findings from the baseline characteristics of participants indicate a diverse patient population.
The combination of binimetinib and palbociclib shows promise for targeting specific cancer markers.
Significant clinical implications could be seen from molecular selection in advanced breast cancer therapy.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase IB study evaluates combined treatment with binimetinib and palbociclib in patients with advanced triple-negative breast cancer, suggesting potential benefits.

Abstract

Baseline characteristics.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Manso et al. (2025) studied this question.

synapsesocial.com/papers/68dc26188a7d58c25ebb27d0 https://doi.org/10.1158/2767-9764.30233484

View Full Paper

Ask AI

Bookmark

Implication

Phase IB study evaluates combined treatment with binimetinib and palbociclib in patients with advanced triple-negative breast cancer, suggesting potential benefits.

Abstract

Baseline characteristics.

Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Table 1 from A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading